GTS Securities’s Biodesix BDSX Stock Holding History

GTS Securities’s Portfolio BDSX Stock Details BDSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,017	Closed	-$143K	–	1530
2024 Q3	$143K	Buy	+4,017	New	+$138K	﹤0.01%	3736

Other funds holding BDSX

Telemark Asset Management Boston, Massachusetts $1.08B AUM 70.88% 1-Year Est. Return

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Samjo Management New York $231M AUM 13.04% 1-Year Est. Return

GTS Securities's BDSX Position: Q4 2024 in Review

GTS Securities sold out of Biodesix (BDSX) in Q4 2024, closing a stake of 4,017 shares — an estimated $143K sold.

GTS Securities first reported a position in BDSX in Q3 2024 and held it in 1 quarter. The position peaked at $143K in Q3 2024. 58 funds tracked by Wall St. Rank hold BDSX as of Q4 2024.

GTS Securities reported no remaining Biodesix position as of Q4 2024 after selling out during the quarter.
GTS Securities sold 4,017 Biodesix shares in Q4 2024, an estimated $143K.
GTS Securities first reported a position in Biodesix in Q3 2024 and held it in 1 quarter.
GTS Securities's Biodesix position peaked at $143K in Q3 2024.
58 funds tracked by Wall St. Rank held Biodesix as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.